UNSPSC 51112304: Improsulfan tosilate

This classification denotes an alkylsulfonate compound with the molecular formula C8H19NO6S2.C7H8O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V878J97JFF, chemically known as bis(3-methylsulfonyloxypropyl)amine p-toluenesulfonate, but more generally known as improsulfan tosilate, which bears US NIH Compound Identifier 153709. European Medicines Agency schedules improsulfan tosilate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08160MIG.

Most nations, for tariff purposes, schedule improsulfan tosilate under HS 29221980. SMILES: CC1CCC(CC1)S(=O)(=O)O.CS(=O)(=O)OCCCNCCCOS(=O)(=O)C.

UNSPSC 51112304 Improsulfan tosilate is a Commodity code for a pharmaceutical active ingredient used in cancer chemotherapy and immunosuppressive treatments. State and local governments purchase this drug primarily through health agencies, Medicaid programs, and public hospital systems to support patient care in oncology and transplant programs. The issuing bodies are typically state health and human services departments and their pharmacy benefit programs rather than counties, cities, or school districts; the code reflects procurement of a narrowly defined pharmaceutical product for clinical use in state-operated or state-funded healthcare delivery systems.

Recent activity shows limited direct solicitation under this specific code. The Texas Health and Human Services Commission issued RFI HHS0017013 in March 2026 to explore direct-to-manufacturer prescription programs that could include branded and generic pharmaceuticals, including improsulfan tosilate formulations, as part of a broader therapeutic pharmacy initiative. The RFI sought vendor capabilities for direct contracting with state agencies and self-insured plans outside traditional pharmacy benefit manager and group purchasing organization channels, with a response date of April 3, 2026. This represents exploratory procurement activity rather than a binding contract award; the state indicated it would use vendor responses to design formal procurement specifications before issuing an RFP. Geographic activity centers on Texas, with no supporting evidence of concurrent solicitation in other states under this code tier. The narrowness of the Commodity code and the preliminary nature of the Texas RFI suggest limited near-term opportunity volume; interested vendors should monitor state Medicaid formulary updates and health department pharmaceutical contracts for more detailed sourcing solicitations.